These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 18675868)

  • 61. Live attenuated Leishmania infantum centrin deleted mutant (LiCen
    Zarei Z; Mohebali M; Dehghani H; Khamesipour A; Tavakkol-Afshari J; Akhoundi B; Abbaszadeh-Afshar MJ; Alizadeh Z; Eskandari SE; Asl AD; Razmi GR
    Comp Immunol Microbiol Infect Dis; 2023 Jun; 97():101984. PubMed ID: 37119594
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Phase I and II Clinical Trial Comparing the LBSap, Leishmune
    Aguiar-Soares RDO; Roatt BM; Mathias FAS; Reis LES; Cardoso JMO; Brito RCF; Ker HG; Corrêa-Oliveira R; Giunchetti RC; Reis AB
    Vaccines (Basel); 2020 Nov; 8(4):. PubMed ID: 33212786
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A new Leishmania-specific hypothetical protein and its non-described specific B cell conformational epitope applied in the serodiagnosis of canine visceral leishmaniasis.
    Lage DP; Martins VT; Duarte MC; Costa LE; Garde E; Dimer LM; Kursancew AC; Chávez-Fumagalli MA; de Magalhães-Soares DF; Menezes-Souza D; Roatt BM; Machado-de-Ávila RA; Soto M; Tavares CA; Coelho EA
    Parasitol Res; 2016 Apr; 115(4):1649-58. PubMed ID: 26782811
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cytokine Profile of Leishmania Infantum Fucose-Mannose Ligand in Vaccinated Dogs in the Northwest of Iran.
    Mohammadi-Ghalehbin B; Hatam G; Sarkari B; Mohebali M; Zarei Z; Bohlooli S
    Iran J Immunol; 2017 Dec; 14(4):293-305. PubMed ID: 29276182
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Randomized, controlled, double-blinded field trial to assess Leishmania vaccine effectiveness as immunotherapy for canine leishmaniosis.
    Toepp A; Larson M; Wilson G; Grinnage-Pulley T; Bennett C; Leal-Lima A; Anderson B; Parrish M; Anderson M; Fowler H; Hinman J; Kontowicz E; Jefferies J; Beeman M; Buch J; Saucier J; Tyrrell P; Gharpure R; Cotter C; Petersen C
    Vaccine; 2018 Oct; 36(43):6433-6441. PubMed ID: 30219369
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Molecular, biochemical characterization and assessment of immunogenic potential of cofactor-independent phosphoglycerate mutase against Leishmania donovani: a step towards exploring novel vaccine candidate.
    Tandon R; Chandra S; Baharia RK; Misra P; Das S; Rawat K; Siddiqi MI; Sundar S; Dube A
    Parasitology; 2018 Apr; 145(4):508-526. PubMed ID: 28691653
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Immunological characterization of rLdTCP1γ for its prophylactic potential against visceral leishmaniasis in hamster model.
    Anand A; Balodi DC; Ramalingam K; Yadav S; Goyal N
    Mol Immunol; 2022 Jan; 141():33-42. PubMed ID: 34798496
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Diagnostic accuracy of rKLO8 versus rK26 ELISAs for screening of canine visceral leishmaniasis.
    Martínez Abad LP; Almeida CS; Mattos AMM; Mendonça ACP; Alves MJM; Pinheiro AC; Porrozzi R; Abass E; Steinhoff U; Teixeira HC
    Acta Trop; 2017 Feb; 166():133-138. PubMed ID: 27876645
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Leishmania donovani serine protease encapsulated in liposome elicits protective immunity in experimental visceral leishmaniasis.
    Das P; Paik D; Naskar K; Chakraborti T
    Microbes Infect; 2018 Jan; 20(1):37-47. PubMed ID: 28970116
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Therapeutic vaccine of killed Leishmania amazonensis plus saponin reduced parasite burden in dogs naturally infected with Leishmania infantum.
    Viana KF; Lacerda G; Teixeira NS; Rodrigues Cangussu AS; Sousa Aguiar RW; Giunchetti RC
    Vet Parasitol; 2018 Apr; 254():98-104. PubMed ID: 29657019
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Studies on the protective efficacy and immunogenicity of Hsp70 and Hsp83 based vaccine formulations in Leishmania donovani infected BALB/c mice.
    Kaur J; Kaur T; Kaur S
    Acta Trop; 2011 Jul; 119(1):50-6. PubMed ID: 21530477
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Development of Immunological Assays Based on
    Ejazi SA; Saha S; Bhattacharyya A; Das S; Mateus NLF; da Costa Lima MS; Neitzke-Abreu HC; de Mendonca IL; Costa CHN; de Oliveira Melo OA; de Melo MA; Rossi-Bergmann B; Corso R; Manna L; Ali N
    Front Cell Infect Microbiol; 2022; 12():914477. PubMed ID: 35846748
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The mass use of deltamethrin collars to control and prevent canine visceral leishmaniasis: A field effectiveness study in a highly endemic area.
    Leite BMM; Solcà MDS; Santos LCS; Coelho LB; Amorim LDAF; Donato LE; Passos SMS; Almeida AO; Veras PST; Fraga DBM
    PLoS Negl Trop Dis; 2018 May; 12(5):e0006496. PubMed ID: 29758031
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Evaluation of the immunogenicity and protective efficacy of killed Leishmania donovani antigen along with different adjuvants against experimental visceral leishmaniasis.
    Thakur A; Kaur H; Kaur S
    Med Microbiol Immunol; 2015 Aug; 204(4):539-50. PubMed ID: 25432859
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge.
    Rodríguez-Cortés A; Ojeda A; López-Fuertes L; Timón M; Altet L; Solano-Gallego L; Sánchez-Robert E; Francino O; Alberola J
    Vaccine; 2007 Nov; 25(46):7962-71. PubMed ID: 17942199
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN).
    da Silva VO; Borja-Cabrera GP; Correia Pontes NN; de Souza EP; Luz KG; Palatnik M; Palatnik de Sousa CB
    Vaccine; 2000 Dec; 19(9-10):1082-92. PubMed ID: 11137242
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis.
    Fujiwara RT; Vale AM; França da Silva JC; da Costa RT; Quetz Jda S; Martins Filho OA; Reis AB; Corrêa Oliveira R; Machado-Coelho GL; Bueno LL; Bethony JM; Frank G; Nascimento E; Genaro O; Mayrink W; Reed S; Campos-Neto A
    Vet Res; 2005; 36(5-6):827-38. PubMed ID: 16120256
    [TBL] [Abstract][Full Text] [Related]  

  • 78. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.
    Bhowmick S; Ravindran R; Ali N
    Infect Immun; 2008 Mar; 76(3):1003-15. PubMed ID: 18195029
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant.
    Schaut RG; Grinnage-Pulley TL; Esch KJ; Toepp AJ; Duthie MS; Howard RF; Reed SG; Petersen CA
    Vaccine; 2016 Oct; 34(44):5225-5234. PubMed ID: 27665354
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs.
    Saldarriaga OA; Travi BL; Park W; Perez LE; Melby PC
    Vaccine; 2006 Mar; 24(11):1928-40. PubMed ID: 16310897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.